Partnership to develop gene editing therapies for neurological, muscular diseases
Regeneron Pharmaceuticals Inc. and Intellia Therapeutics Inc. have announced an expanded research collaboration aimed at developing further CRISPR-based gene-editing therapies focused on neurological and muscular diseases. According to an Intellia press release, the expanded partnership aims to combine Regeneron’s proprietary adeno-associated viral vectors and antibody-targeted delivery systems with Intellia’s proprietary Nme2 CRISPR/Cas9 systems tailored to […]
